Dataset from COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the
nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.

TAFFIX is approved as a medical device in Israel, intended for use to block inhaled viruses
within the nasal cavity. In Europe, it is registered as a medical device indicated for use as
a protective mechanical barrier against allergens and viruses (e.g., SARS-CoV-2) within the
nasal cavity.

TAFFIX is used as additional safety mean together with masks, hygiene, and social distancing.

The study rationale is to evaluate whether daily use of TaffiX™ as prophylaxis will reduce
the rate of SARS- CoV-2 infection and other upper respiratory infections, compared to the
placebo control rate.